Cargando…

Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals

Chronic infection with hepatitis C virus (HCV) may complicate with hepatocellular carcinoma (HCC), especially in patients with cirrhosis. Although the achievement of a sustained virological response (SVR) had been associated with a reduction in the risk of HCC already in the Interferon era, some con...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Ambrosio, Roberta, Degasperi, Elisabetta, Lampertico, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254542/ https://www.ncbi.nlm.nih.gov/pubmed/34235108 http://dx.doi.org/10.2147/JHC.S292139

Ejemplares similares

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon
por: D’Ambrosio, Roberta, et al.
Publicado: (2016)

Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma
por: Sohn, Won
Publicado: (2021)

Hepatocellular carcinoma after a sustained virological response by direct‐acting antivirals harbors TP53 inactivation
por: Imamura, Taisuke, et al.
Publicado: (2022)

Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
por: Dash, Srikanta, et al.
Publicado: (2020)

Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies
por: Degasperi, Elisabetta, et al.
Publicado: (2022)

Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
por: Dias, Cátia, et al.
Publicado: (2018)

2224. Receipt and Virologic Outcomes of HCV Direct-Acting Antivirals by Alcohol Use and HIV Status
por: Cartwright, Emily J, et al.
Publicado: (2018)

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis
por: Kuwano, Toru, et al.
Publicado: (2018)

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
por: Struble, Kimberly, et al.
Publicado: (2019)

A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C
por: Yoshida, Yuji, et al.
Publicado: (2023)

Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2020)

Liver Remodeling on CT Examination in Patients with HCV Compensated Cirrhosis Who Achieved Sustained Virological Response after Direct-Acting Antivirals Treatment
por: Mihai, Florin, et al.
Publicado: (2020)

Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid
por: Pham, Timothy T., et al.
Publicado: (2018)

The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence
por: Cavalletto, Luisa, et al.
Publicado: (2023)

Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals
por: Noureddin, Mazen, et al.
Publicado: (2018)

Mixed cryoglobulinaemia vasculitis after sustained hepatitis C virological response with direct-acting antivirals
por: Barbieri, Diego, et al.
Publicado: (2018)

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
por: Cartwright, Emily J., et al.
Publicado: (2023)

L3 Skeletal Muscle Index Dynamics in Patients with HCV-Related Compensated Cirrhosis Following Sustained Virological Response after Direct Acting Antiviral Treatment
por: Mihai, Florin, et al.
Publicado: (2021)

Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral–induced sustained virologic response
por: Franco, Sandra, et al.
Publicado: (2023)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
por: Rinaldi, Luca, et al.
Publicado: (2020)

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals
por: Vernuccio, Federica, et al.
Publicado: (2022)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
por: Morgan, Jake R., et al.
Publicado: (2021)

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
por: Tada, Toshifumi, et al.
Publicado: (2021)

Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment
por: Hahn, Katherine J., et al.
Publicado: (2015)

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C
por: Pan, Jason J., et al.
Publicado: (2018)

Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes
por: Piedade, Juliana, et al.
Publicado: (2021)

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
por: Sanduzzi-Zamparelli, Marco, et al.
Publicado: (2019)

Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs
por: Serio, Ilaria, et al.
Publicado: (2019)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
por: Na, Seong Kyun, et al.
Publicado: (2019)

Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis
por: Radhakrishnan, Kavita, et al.
Publicado: (2019)

Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals
por: El-Kassas, Mohamed, et al.
Publicado: (2023)

Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct‐acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance
por: Tada, Toshifumi, et al.
Publicado: (2022)

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
por: Pellicelli, Adriano M, et al.
Publicado: (2012)

Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response
por: García-Ros, Alejandro, et al.
Publicado: (2023)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Resolved HBV behavior during the treatment of chronic HCV infection with direct-acting antivirals
por: Mohamed, Salem Y., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hcnrru3dt37gti3lritfnm99lv